Ketotherapeutics for neurodegenerative diseases | Zendy

Nicholas G. Norwitz | Zendy; Javier GilbertJaramillo | Zendy; Kieran Clarke | Zendy; Adrián Soto-Mota | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ketotherapeutics for neurodegenerative diseases

Author(s) -

Nicholas G. Norwitz,

Javier GilbertJaramillo,

Kieran Clarke,

Adrián Soto-Mota

Publication year - 2020

Publication title -

international review of neurobiology

Language(s) - English

Resource type - Journals

eISSN - 2162-5514

pISSN - 0074-7742

DOI - 10.1016/bs.irn.2020.02.003

Subject(s) - disease , neuroscience , ketone bodies , neurodegeneration , parkinson's disease , medicine , motor symptoms , bioinformatics , psychology , biology , pathology , metabolism

Alzheimer's disease (AD) and Parkinson's disease (PD) are, respectively, the most prevalent and fastest growing neurodegenerative diseases worldwide. The former is primarily characterized by memory loss and the latter by the motor symptoms of tremor and bradykinesia. Both AD and PD are progressive diseases that share several key underlying mitochondrial, inflammatory, and other metabolic pathologies. This review will detail how these pathologies intersect with ketone body metabolism and signaling, and how ketone bodies, particularly d-β-hydroxybutyrate (βHB), may serve as a potential adjunctive nutritional therapy for two of the world's most devastating conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research